22 search results for: disease progression

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

expert video

UEGW 2024 | WHAT Can Be Used to Monitor Treatment Response in EoE and WHEN?

11 min

Gastroenterology

Dr. Milli Gupta emphasizes the need to regularly monitor multiple disease domains when assessing treatment response, not just EoE symptoms.

expert video

More Than Eosinophils: A Closer Look at the Pathophysiology of EoE

20 min

Gastroenterology

Join Prof. Kathryn Peterson for an expert review on how different immune cells and inflammatory mediators contribute to the pathogenesis of EoE.

expert video

Importance of Early Diagnosis of Pediatric EoE

4 min

Gastroenterology

Learn from Prof. Papadopoulou as she highlights challenges in identifying EoE in pediatric patients and the consequences of delayed diagnosis.

expert video

Interplay of Barrier Dysfunction and Type 2 Inflammation in EoE

2 min

Gastroenterology

Learn from Prof. Seema Aceves about the interconnectivity of type 2 inflammation and barrier dysfunction in mediating EoE pathophysiology.

expert video

Patient Burden in Eosinophilic Esophagitis

3 min

Gastroenterology

Drs. Kathryn Peterson and Ikuo Hirano and Profs. Ingrid Terreehorst and Arjan Bredenoord highlight the impact and burden of EoE on the quality of life of patients.

expert video

UEGW 2024 | Something to Chew On: Exploring the Management of EoE

24 min

Gastroenterology

Prof. Salvatore Oliva and Dr. Milli Gupta discuss the importance of long-term care and multidimensional assessment.

expert video

ERS 2024 | Understanding the Complex Pathophysiology of COPD

6 min

Pulmonology

Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.

expert video

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention

25 min

Dermatology

This video from the March 2024 ADVENT AD symposium features Dr. Lawrence Eichenfield presenting the systemic burdens of AD in children and the need for early intervention. Dr. Eichenfield also reviews the multidimensional, atopic, and non-atopic burdens associated with AD in pediatric patients. He goes on to discuss evidence on benefits of early intervention and how it may prevent the progression of local and systemic inflammatory processes over time, followed by a brief panel discussion.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region